OmniAb Inc offers therapeutic antibody discovery technologies. The company focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable theefficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.

$427.2M

Market Cap • 12/25/2024

2012

(12 years)
Founded

2022

(2 years ago)
IPO

NASDAQ

Listing Exchange
Flag of US

Emeryville

Headquarters • California